PhD, with all due respect, aren’t you, and many others, comparing apples to oranges? The folks speaking on the efficacy of CaverStem 2 years ago were spot on. They likely knew the data from Gershman and all the patients he treated. The paper had a long way to go, and was delayed much longer when they added the 2.0 folks, but praising CaverStem’s efficacy was spot on, as we now see proven in writing. Like even Big said today, there is no disputing the science and efficacy.
Comparing that to the company side of the house that fell victim to many things, putting us where we are at today doesn’t seem fair. I would even argue that many of the doctors are shareholders too and will be riding this RS out just the same as all shareholders.
None of us know what Tim has in store for CELZ. I have heard both good and bad things could be ahead. The shareholders, including any doctors, will all find out at the same time.